Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human FLT4/VEGFR3 Antibody (SAA2200)

Catalog #:   FHE16510 Specific References (43) DATASHEET
Host species: Human
Isotype: IgG1, kappa
Applications: ELISA, FCM
Accession: P35916
Overview

Catalog No.

FHE16510

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

Unconjugated

Target

Vascular endothelial growth factor receptor 3, VEGFR-3, Fms-like tyrosine kinase 4, Tyrosine-protein kinase receptor FLT4, FLT-4, VEGFR3, FLT4

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P35916

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

SAA2200

Data Image
References

The Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling., PMID:38888964

Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients., PMID:38349411

In Silico Evaluation of HN-N07 Small Molecule as an Inhibitor of Angiogenesis and Lymphangiogenesis Oncogenic Signatures in Non-Small Cell Lung Cancer., PMID:37509650

Plasma protein changes reflect colorectal cancer development and associated inflammation., PMID:37228491

Hypoxia-inducible factor pathway genes predict survival in metastatic clear cell renal cell carcinoma., PMID:35973929

Quantitative Three-Dimensional Analysis of the Lymphatic Vasculature in the Postnatal Mouse Heart., PMID:35099736

Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma., PMID:34755131

Anti-Vascular Endothelial Growth Factor C Antibodies Efficiently Inhibit the Growth of Experimental Clear Cell Renal Cell Carcinomas., PMID:34067671

Highly expressed Claudin18.2 as a potential therapeutic target in advanced gastric signet-ring cell carcinoma (SRCC)., PMID:33457012

An immunohistochemical study of lymphatic elements in the human brain., PMID:33446503

Pre-therapeutic Biomarkers for Ranibizumab Therapy among Type 2 Diabetic Patients with Diabetic Macular Edema., PMID:33394935

Absence of lymphatic vessels in term placenta., PMID:32600346

Lymphatic and Immune Cell Cross-Talk Regulates Cardiac Recovery After Experimental Myocardial Infarction., PMID:32404007

Influence of buffy coat-derived putative endothelial progenitor cells on tumor growth and neovascularization in oral squamous cell carcinoma xenografts., PMID:30693401

Lymphatic vessels identified in failed corneal transplants with neovascularisation., PMID:30348644

Anti-metastatic Efficacy of Traditional Chinese Medicine (TCM) Ginsenoside Conjugated to a VEFGR-3 Antibody on Human Gastric Cancer in an Orthotopic Mouse Model., PMID:28314255

LPS Upregulated VEGFR-3 Expression Promote Migration and Invasion in Colorectal Cancer via a Mechanism of Increased NF-κB Binding to the Promoter of VEGFR-3., PMID:27639612

Development of Lymphatic Capillary Network Along the Alveolar Walls of Autopsied Human Lungs with Pneumonia., PMID:27617628

Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer., PMID:27566701

Blockade of FLT4 suppresses metastasis of melanoma cells by impaired lymphatic vessels., PMID:27507214

Platelet interaction with lymphatics aggravates intestinal inflammation by suppressing lymphangiogenesis., PMID:27313177

Expression of factors involved in the regulation of angiogenesis in the full-term human placenta: Effects of in vitro fertilization., PMID:27288334

Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival., PMID:26394830

Vascular endothelial growth factor C disrupts the endothelial lymphatic barrier to promote colorectal cancer invasion., PMID:25754161

The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking., PMID:25690013

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma., PMID:25665807

Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance., PMID:24713547

Polymorphisms in vascular endothelial growth factor receptor 2 are associated with better response rates to ranibizumab treatment in age-related macular degeneration., PMID:24365177

Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection., PMID:23935036

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer., PMID:23908119

Blockade of VEGF receptor-3 aggravates inflammatory bowel disease and lymphatic vessel enlargement., PMID:23835443

New pharmaceutical treatment of gastric MALT lymphoma: anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib., PMID:23782142

Localization and signaling patterns of vascular endothelial growth factors and receptors in human periapical lesions., PMID:23611377

Signaling for lymphangiogenesis via VEGFR-3 is required for the early events of metastasis., PMID:23591595

Effects of vascular endothelial growth factor-C and -D on osteoclast differentiation and function in human peripheral blood mononuclear cells., PMID:22771550

The lymphatic system in clinically localized urothelial carcinoma of the bladder: morphologic characteristics and predictive value., PMID:22503575

The role of the VEGF-C/-D/flt-4 autocrine loop in the pathogenesis of salivary neoplasms., PMID:22326635

Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy., PMID:22130231

Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer., PMID:21224365

Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions., PMID:20949568

Suppression of lymphangiogenesis induced by Flt-4 antibody in gastric low-grade mucosa-associated lymphoid tissue lymphoma by Helicobacter heilmannii infection., PMID:20586849

The role of estrogen receptors, erbB receptors, vascular endothelial growth factor and its receptors, and vascular endothelial growth inhibitor in the development of the rat mammary gland., PMID:20572782

Lymphatic capillary hypoplasia in the skin of fetuses with increased nuchal translucency and Turner's syndrome: comparison with trisomies and controls., PMID:20457798

Datasheet
$ 198
Product specifications
50 μg 198 100 μg 328

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human FLT4/VEGFR3 Antibody (SAA2200) [FHE16510]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only